

As required under MAS Notice 637 and in line with Basel III requirements, **Tables 1 and 2** are mandatory disclosures on Regulatory Capital using prescribed templates.

Table 1 shows the reconciliation between the Group's published consolidated balance sheet and the regulatory capital components. The balance sheet is expanded to identify and map to the regulatory capital components as set out in Table 2 (in the column "Reference").

The scope of consolidation for accounting and regulatory purposes is similar, except that subsidiaries which carry out insurance business are not consolidated for regulatory purpose. The list of the Group's major insurance subsidiaries can be found in the Annual Report. As at 31 Dec 2016, the total assets or total equities of each of these subsidiaries were less than S\$1 billion.

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 31 Dec 2016

Table 1 - Reconciliation of Balance Sheet to Regulatory Capital as at 31 Dec 2016	15	T	
	Balance sheet	Under	
	as per published	regulatory	
	financial	scope of	
S\$ million	statements	consolidation	Reference
Equity			
Share capital and other capital	6,351		
of which: Paid-up ordinary shares	4,257	4,257	Α
of which: AT1 capital instruments	2,094	2,094	В
Retained earnings	17,334	17,226	С
Other reserves	9,189	9,146	D
Equity attributable to equity holders of the Bank	32,873	,	
Non-controlling interests	169		
of which: Transitional: Ineligible surplus NCI of bank subsidiaries		0	E1
of which: NCI that meets criteria for inclusion in			
- CET1 capital		12	E2
- AT1 capital		2	E3
- T2 capital		3	E4
Total equity	33,042	J	
Liabilities	00,042		
Deposits and balances of banks	11,855		
Deposits and balances of non-bank customers	255,314		
Bills and drafts payable	522		
Other liabilities	13.152		
Debts issued	26,143		
of which: Transitional: Ineligible T2 capital instruments	1,918	1,918	F1
of which: T2 capital instruments	3,628	3,628	F2
Total liabilities	306,986	3,020	ГZ
	300,960		
Assets Cash, balances and placements with central banks	24,322		
Singapore Government treasury bills and securities	6,877		
Other government treasury bills and securities	10,638		
Trading securities	3,127		
Placements and balances with banks			
	40,033		
Loans to non-bank customers of which: Provisions eligible for inclusion in T2 capital	221,734	1 110	G
Investment securities ¹	44.040	1,119	G
	11,640	E4	
of which: Investment in PE/VC exceeding 20% shareholding or holding period Other assets ¹	40.407	51	Н
	13,407	225	<u> </u>
of which: Amount related to deferred tax assets (net of deferred tax liabilities, where permissible)		265	<u> </u>
Investment in associates and joint ventures ¹	1,109		
of which: Amount related to goodwill		7	J1
Investment properties	1,105		
Fixed assets	1,885		
Intangible assets	4,151		
of which: Amount related to goodwill		4,151	J2
Investments approved under s32 of the Banking Act and insurance subsidiaries			
of which: Ordinary shares subject to threshold deduction		-	K1
of which: AT1 capital instruments		4	K2
Indirect investments in own capital instruments	-	1	L
Total Assets	340,028		

Abbreviation: CET1: Common Equity Tier 1; AT1: Additional Tier 1; T2: Tier 2; PE/VC: Private Equity and Venture Capital

Note:

¹ This includes investments approved under s32 of the Banking Act such as equity investments in investee companies exceeding 10% shareholding





Table 2 lists the regulatory capital components and the corresponding regulatory adjustments. The columns: (a) 'Amount' refers to components of capital calculated in accordance with MAS Notice 637, effective 1 Jan 2013, (b) 'Amount subject to Pre-Basel III Treatment' refers to components of capital that are on transitional arrangement, otherwise would be fully applied towards the relevant tier of capital, and (c) 'Source' provides link to Table 1 by way of alphabetic / alphanumeric references, and cross-reference within the table by way of row number. Regulatory adjustments that are deducted against capital are reflected as positive numbers. Amounts less than \$500,000 in absolute terms are shown as "0".

Table 2 - Capital Components as at 31 Dec 2016

Table	2 - Capital Components as at 31 Dec 2016			
	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
	Common Equity Tier 1 capital: instruments and reserves	7		334.33
1	Paid-up ordinary shares and share premium (if applicable)	4,257	1	Α
2	Retained earnings	17,226	-	C
3#	Accumulated other comprehensive income and other disclosed reserves	9,146	-	D
4	Directly issued capital subject to phase out from CET1		-	
	(only applicable to non-joint stock companies)			
5	Minority interest that meets criteria for inclusion	13	(0)	E1+E2, -E1
6	Common Equity Tier 1 capital before regulatory adjustments	30,641	(0)	
	Common Equity Tier 1 capital: regulatory adjustments	30,041	-	
7	Valuation adjustment pursuant to Part VIII of MAS Notice 637	_	-	
8	Goodwill, net of associated deferred tax liability	2,495	1,663	J1+J2
9#	Intangible assets, net of associated deferred tax liability	2,433	1,005	31702
10#		159	106	1
_	Deferred tax assets that rely on future profitability	109	100	'
11	Cash flow hedge reserve	-	-	
12	Shortfall of TEP relative to EL under IRBA	-	-	
13	Increase in equity capital resulting from securitisation transactions	-	-	
14	Unrealised fair value gains/losses on financial liabilities and derivative liabilities	-	-	
	arising from changes in own credit risk			
15	Defined benefit pension fund assets, net of associated deferred tax liability	-		_
16	Investments in own shares	0		L
17	Reciprocal cross-holdings in ordinary shares of financial institutions	-		
18	Capital investments in ordinary shares of unconsolidated financial institutions	-		
	in which Reporting Bank does not hold a major stake			
19#	Investments in ordinary shares of unconsolidated major stake companies	-	-	K1
	approved under s32 of Banking Act (including insurance subsidiaries)			
	(amount above 10% threshold)			
20#	Mortgage servicing rights (amount above 10% threshold)	-		
21#	Deferred tax assets arising from temporary differences	-		
	(amount above 10% threshold, net of related tax liability)			
22	Amount exceeding the 15% threshold	-		
23#	of which: investments in ordinary shares of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (including insurance subsidiaries)			
24#	of which: mortgage servicing rights	-		
25#	of which: deferred tax assets arising from temporary differences	-		
26	National specific regulatory adjustments	31		
26A	PE/VC investments in the form of ordinary shares, in excess of 20%	31	21	Н
	of such capital investments			
26B	PE/VC investments held beyond the relevant holding periods set out in MAS Notice 630	0	0	Н
	Capital deficits in subsidiaries and associates that are regulated financial institutions	_	_	
26D	Any other items which the Authority may specify	-		
27	Regulatory adjustments applied in calculation of CET1 Capital due to insufficient	_		
	AT1 Capital to satisfy required deductions			
28	Total regulatory adjustments to CET1 Capital	2,685		
29	Common Equity Tier 1 capital (CET1)	27,956	-	
23	Additional Tier 1 capital: instruments	21,930		
30	AT1 capital instruments and share premium (if applicable)	2.004		В
30		2,094		D
31	of which: classified as equity under the Accounting Standards	2,094		
32	of which: classified as liabilities under the Accounting Standards	-		
33	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	-		F2
34	AT1 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	2		E3
35	of which: instruments issued by subsidiaries subject to phase out	-		
36	Additional Tier 1 capital before regulatory adjustments	2,096		
	Additional Tier 1 capital: regulatory adjustments			
37	Investments in own AT1 capital instruments	0		L
38	Reciprocal cross-holdings in AT1 capital instruments of financial institutions	-		
39	Capital investments in AT1 capital instruments of unconsolidated financial institutions	-		
<u></u>	in which Reporting Bank does not hold a major stake			





Table 2 - Capital Components as at 31 Dec 2016

Table	e 2 - Capital Components as at 31 Dec 2016	1	I A	
	S\$ million	Amount	Amount subject to Pre-Basel III Treatment	Source
40 [#]	Investments in AT1 capital instruments of unconsolidated major stake companies	3	1	K2
	approved under s32 of Banking Act (including insurance subsidiaries)			
41	National specific regulatory adjustments	1,769		
41A	PE/VC investments in the form of AT1 capital instruments, in excess of 20%	-	-	
	of such capital investments			
41B	Any other items which the Authority may specify	-		
41C	Regulatory adjustments applied to AT1 Capital in respect of amounts subject to pre-Basel III treatment	1,769		
	of which: Goodwill, net of associated deferred tax liability	1,663		row 8 at 40%
	of which: Intangible assets, net of associated deferred tax liability	- 1,000		1011 0 01 1070
	of which: Deferred tax assets that rely on future profitability	106		row 10 at 40%
	of which: Cash flow hedge reserve	-		1011 10 41 1070
	of which: Increase in equity capital resulting from securitisation transactions	_		
	of which: Unrealised fair value gains/losses on financial liabilities and derivative liabilities	_		
	arising from changes in own credit risk			
	of which: Shortfall of TEP relative to EL under IRBA	-		
	of which: PE/VC investments in the form of ordinary shares, in excess of 20%	-		
	of such capital investments			
	of which: PE/VC investments held beyond the relevant holding periods set out in	-		
	MAS Notice 630 of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	_	-	
	of which: Investments in ordinary shares of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (incl insurance subsidiaries)			
	of which: PE/VC investments in the form of Tier 2 capital instruments, in excess of 20%	-		
	of such capital investments			
	of which: Investments in Tier 2 capital instruments of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (incl insurance subsidiaries)			
42	Regulatory adjustments applied in calculation of AT1 Capital due to	-		
	insufficient Tier 2 Capital to satisfy required deductions			
43	Total regulatory adjustments to Additional Tier 1 capital	1,772		
44	Additional Tier 1 capital (AT1)	324		
45	Tier 1 capital (T1 = CET1 + AT1)	28,280		
	Tier 2 capital: instruments and provisions			
46	Tier 2 capital instruments and share premium (if applicable)	3,628		F2
47	Transitional: Ineligible capital instruments (pursuant to paragraphs 6.5.3 and 6.5.4)	1,918		F1
48	Tier 2 capital instruments issued by fully-consolidated subsidiaries that meet criteria for inclusion	3		E4
49	of which: instruments issued by subsidiaries subject to phase out	-		
50	Provisions	1,119		G
51	Tier 2 capital before regulatory adjustments	6,668		
	Tier 2 capital: regulatory adjustments			
52	Investments in own Tier 2 instruments	0		L
53	Reciprocal cross-holdings in Tier 2 capital instruments of financial institutions	-		
54	Capital investments in Tier 2 capital instruments of unconsolidated financial institutions	-		
	in which Reporting Bank does not hold a major stake			
55 [#]	Investments in Tier 2 capital instruments of unconsolidated major stake companies	-	-	
	approved under s32 of Banking Act (including insurance subsidiaries)			
56	National specific regulatory adjustments	21		
56A	PE/VC investments in the form of Tier 2 capital instruments, in excess of 20% of such capital investments	-	-	
56B	Any other items which the Authority may specify	-		
	Regulatory adjustments applied to Tier 2 Capital in respect of amounts	21		
	subject to pre-Basel III treatment			
	of which: Shortfall of TEP relative to EL under IRBA	-		
	of which: PE/VC investments in the form of ordinary shares, in excess of 20%	21		row 26A at 40%
	of such capital investments of which: PE/VC investments held beyond the relevant holding periods set out in	0		row 26B at 40%
	MAS Notice 630			10W 20D at 40 /0
	of which: Capital deficits in subsidiaries and associates that are regulated financial institutions	-		
	of which: Investments in ordinary shares of unconsolidated major stake companies	-		
	approved under s32 of Banking Act (incl insurance subsidiaries)			
l	of which: PE/VC investments in the form of AT1 capital instruments, in excess of 20%	-		
	of such capital investments			





Table 2 - Capital Components as at 31 Dec 2016

rabie	able 2 - Capital Components as at 31 Dec 2016		Amount	
			subject to Pre-Basel III Treatment	Source
	S\$ million	Amount		
	of which: Investments in AT1 capital instruments of unconsolidated major stake companies	1		row 40 at 20%
	approved under s32 of Banking Act (incl insurance subsidiaries)			
57	Total regulatory adjustments to Tier 2 capital	22		
58	Tier 2 capital (T2)	6,646		
59	Total capital (TC = T1 + T2)	34,926		
60	Total risk weighted assets	215,559		
	Capital ratios (as a percentage of risk weighted assets)			
61	Common Equity Tier 1 CAR	13.0%		
62	Tier 1 CAR	13.1%		
63	Total CAR	16.2%		
64	Bank-specific buffer requirement	7.168%		
65	of which: capital conservation buffer requirement	0.625%		
66	of which: bank specific countercyclical buffer requirement 1	0.043%		
67	of which: G-SIB buffer requirement (if applicable)	-		
68	Common Equity Tier 1 available to meet buffers	5.1%		
	National minima			
69	Minimum CET1 CAR	6.5%		
70	Minimum Tier 1 CAR	8.0%		
71	Minimum Total CAR	10.0%		
	Amounts below the thresholds for deduction (before risk weighting)			
	Investments in ordinary shares, AT1 capital and Tier 2 capital of unconsolidated financial	312		
	institutions in which the bank does not hold a major stake			
73	Investments in ordinary shares of unconsolidated major stake companies	2,666		
	approved under s32 of Banking Act (including insurance subsidiaries)			
74	Mortgage servicing rights (net of related tax liability)	-		
75	Deferred tax assets arising from temporary differences (net of related tax liability)	-		
	Applicable caps on the inclusion of provisions in Tier 2			
76	Provisions eligible for inclusion in Tier 2 in respect of exposures	366		
	subject to standardised approach (prior to application of cap)			
77	Cap on inclusion of provisions in Tier 2 under standardised approach	287		row 50
78	Provisions eligible for inclusion in Tier 2 in respect of exposures	964		
	subject to internal ratings-based approach (prior to application of cap)			
79	Cap for inclusion of provisions in Tier 2 under internal ratings-based approach	832		row 50
	Capital instruments subject to phase-out arrangements			
	(only applicable between 1 Jan 2013 and 1 Jan 2022)			
80	Current cap on CET1 instruments subject to phase out arrangements	-		
31	Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)	-		
32	Current cap on AT1 instruments subject to phase out arrangements	1,289		
	Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities)	-		
84	Current cap on T2 instruments subject to phase out arrangements	3,128		
_	Amount excluded from T2 due to cap (excess over cap after redemptions and maturities)			

[#] These elements are subject to a more conservative definition relative to those set out under the Basel III capital standards.

Note:



¹ The Group's countercyclical buffer (CCyB) is computed as the weighted average of effective CCyB in jurisdictions to which the Group has private sector exposures. As at 31 Dec 2016, the Group has private sector exposures to Hong Kong and Sweden, whose effective country-specific CCyB is 0.625% for the year of 2016. The weightings applied to Hong Kong and Sweden exposures are 7% and 0% respectively.